Colorectal cancer (CRC) is the third most commonly diagnosed cancer in both men and women in the USA. However, the underlying molecular mechanisms that drive CRC tumorigenesis are still not clear. Several studies have reported that long noncoding RNAs (lncRNAs) have important roles in tumor development. Here, we undertook a transcriptome microarray analysis in 6 pairs of CRC tissues and their corresponding adjacent normal tissues. A total of 1705 differentially expressed lncRNAs were detected in CRC tissues at stages I/II and III/IV (fold change greater than or equal to 2 or less than or equal to 0.5). Among them, we found that the lncRNA lung cancerassociated transcript 1 (LUCAT1) was upregulated in CRC tissues and was closely associated with poor overall survival of CRC patients, through analysis of clinical data and The Cancer Genome Atlas. Functional studies indicated that LUCAT1 promoted CRC cell proliferation, apoptosis, migration, and invasion in vitro and in vivo.
| INTRODUC TI ON
Colorectal cancer is the third most commonly diagnosed cancer in both men and women in the USA. The annual age-standardized incidence rate for CRC (2009-2013) was 40.7 per 100 000 persons, and the mortality rate (2010-2014) was 14.8 per 100 000 persons. 1, 2 In China, CRC is the fourth most common malignant cancer with increasing incidence.
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While CRC patients with clinical stage I-II disease have relatively good prognosis, patients with stage III-IV have a poor therapeutic response and prognosis. 4 The underlying molecular mechanisms that drive CRC tumorigenesis remain to be fully elucidated. Accumulating evidence has
shown that lncRNAs have functions in tumor development, and these lncRNAs could provide new candidates for diagnostics and therapy.
Long noncoding RNA is a type of noncoding RNA transcript longer than 200 nucleotides. 5 A large number of studies have indicated that lncRNAs regulate gene expression through chromatin modification, transcription, and post-transcriptional processing. 6, 7 Long noncoding
RNAs have been shown to be differentially expressed in various cancers such as colorectal, breast, and lung cancer, suggesting that they might have roles in tumorigenesis and tumor metastasis, 7 and could act as diagnostic biomarkers in a variety of cancers. 8, 9 Although some lncRNAs have been characterized in CRC with regards to their biological function and mechanisms, 10, 11 the expression pattern of lncRNAs in CRC progression remains unclear.
In this study, we attempted to identify CRC progression-associated lncRNAs. Using lncRNA microarray in clinical samples, we found that LUCAT1 lncRNA has an important role in the regulation of CRC progression and response to chemotherapy, and thus might serve as a potential prognostic marker and therapeutic target.
| MATERIAL S AND ME THODS
Colorectal cancer tissues and corresponding adjacent normal mucosa samples were obtained from 90 patients with CRC who underwent surgical resection at the First Affiliated Hospital of Nanjing Medical University (Nanjing, China). All samples were immediately snap-frozen in liquid nitrogen after collection and stored at −80°C until total RNA was extracted. None of the patients received chemotherapy or radiotherapy before surgical treatment. The clinical information of the CRC patients is summarized in Table 1 . This project was approved by the Research Ethics Committee of Nanjing Medical University (approval ID:
(2016)640). Other materials and methods are described in Appendix S1.
All the primers used for real-time PCR are shown in Table S1 , and all the Abs used in western blotting are shown in Table S2 .
| RE SULTS

| Long noncoding RNA expression profile in CRC tissues
To identify potential lncRNAs involved in CRC progression, we collected primary tumors and the corresponding adjacent normal mucosal tissues from 3 patients with stage I/II and 3 patients with stage III/IV disease, and then undertook a transcriptome microarray in which protein-coding mRNAs and lncRNAs were included. With filtering conditions of fold change greater than or equal to 2 or less than or equal to 0.5 and P < 0.05, a total of 2043 protein-coding mRNAs were detected as differentially expressed between CRC and normal tissues ( Figure 1A ). Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis revealed that these differentially expressed genes were significantly enriched in the cell cycle, in cytokinecytokine receptor interactions, RNA polymerases, DNA replication, and the p53 signaling pathway ( Figure 1B ). Abnormally expressed lncRNAs in CRC tissues are shown in Figure 1C . In total, 1705 differently expressed lncRNAs were detected in CRC tissues at both I/II and III/IV stages (fold change more than or equal to 2, or less than or equal to 0.5, P < 0.05). Among them, 896 were upregulated and 809 were downregulated in all CRC tissues.
| LUCAT1 is upregulated in CRC and is associated with poor prognosis
Among the upregulated lncRNAs, we found that LUCAT1, which is reported to participate in the tumorigenesis of several cancers, was highly expressed in all CRC tissues at different stages. To validate the microarray results, LUCAT1 expression was measured in 90 matched CRC samples using RT-qPCR. Our results showed that the levels of LUCAT1 in CRC tissues were nearly 4.09-fold increased as compared with the corresponding adjacent normal mucosa ( Figure 2A ). The correlation analysis of LUCAT1 expression revealed that increased LUCAT1 levels were significantly associated with advanced CRC TNM stage (P = .0035; Figure 2B ). However, there was no significant association between LUCAT1 expression level and several other clinical parameters such as sex, age, and histological grade in our study (Table 1) .
We further examined the clinical effect of LUCAT1 in CRC by analyzing TCGA database. We compared the data from 599 CRC tissues and 51 normal colon tissues and found that the expression levels of LUCAT1 were significantly increased in CRC tissues by 3.97-fold (P < .0001; Figure 2C ) and were associated with tumor clinical stage ( Figure 2D ). Furthermore, Kaplan-Meier analysis indicated that patients with higher LUCAT1 expression had poorer overall survival than those with low expression of LUCAT1 ( Figure 2E ).
Taken together, these data indicated that LUCAT1 is highly expressed in CRC and is associated with cancer progression and poor prognosis.
| LUCAT1 promotes cell proliferation and invasion in vitro
We next investigated the effect of LUCAT1 in CRC cells. We first screened the expression levels of LUCAT1 in CRC cell lines HCT116, HT29, SW480, RKO, Caco-2, and LoVo and in a normal colonic epithelial cell line, FHC. LUCAT1 expression was found to be significantly higher in CRC cell lines compared with FHC ( Figure 3A ). Based on this result, we selected HCT116 and RKO cells in which to study the biological function of LUCAT1 through loss-and gain-of-function approaches.
Three specific siRNAs and pcDNA-LUCAT1 were transiently transfected into HCT116 and RKO cells. As shown in Figure 3B , siRNAs specifically targeting LUCAT1 decreased the expression of LUCAT1, whereas pcDNA-LUCAT1 transfection increased the expression of LUCAT1. The results from CCK-8 assays showed that siRNAs siLUCAT1-2 and siLUC-AT1-3 reduced the viability of HCT116 and RKO cells. In contrast, overexpression of LUCAT1 significantly increased cell viability ( Figure 3C ). As siLUCAT1-2 showed the best capacity in silencing and growth inhibition, it was chosen to generate the lentivirus for further studies. Colony formation assays revealed that knockdown of LUCAT1 could significantly inhibit cell proliferation in both HCT116 and RKO cell lines, whereas LUCAT1-overexpressing cells showed the opposite effect ( Figure 3D ).
The effect of LUCAT1 on the cell cycle and apoptosis was then Together, these data suggested that LUCAT1 promotes CRC cell proliferation and invasion in vitro.
| LUCAT1 promotes CRC cell proliferation in vivo
To further determine whether LUCAT1 mediates tumorigenesis in than those from the control groups ( Figure 5D ).
We also found that the expression of proliferation marker Ki-67 was significantly decreased in tumors from sh-LUCAT1 cells compared with tumors from control cells ( Figure 5E ). Likewise, the apoptosis marker cleaved PARP-1 was higher in xenograft tumors from the sh-LUCAT1 group than those from the control group ( Figure 5F ).
Collectively, these data implied that suppression of LUCAT1 expression could repress CRC cell proliferation and induce apoptosis in vivo.
| LUCAT1 knockdown confers drug sensitivity in CRC cells
To investigate the role of LUCAT1 in drug responsiveness, we assessed the effects of LUCAT1 knockdown on cell proliferation and 
| Low expression of LUCAT1 correlates with the p53 pathway
To investigate which biological pathways LUCAT1 might be involved in, we undertook Gene Set Enrichment Analysis (GSEA) with 478 CRC tumor samples in TCGA database. Notably, we found that low LUCAT1 expression had a high correlation with the p53 pathway and p53 target gene expression in colon cancer (with the filtering conditions of false discovery rate (FDR) <25% and a nominal P value <.001; Figure 7A ), which was consistent with our previous KEGG analysis data showing that the p53 pathway is involved in CRC ( Figure 1B ). This suggested that LUCAT1 might regulate CRC proliferation and apoptosis by way of the p53 pathway. To validate this, we tested the expression of p53 and its associated genes involved in the cell cycle and apoptosis in LUCAT1-knockdown cells and found that LUCAT1 knockdown increased p53, p21, and Bax expression and decreased the expression of Bcl-2 ( Figure 7B ).
LUCAT1 knockdown induced p53 expression at the protein level but not at the mRNA level, indicating that LUCAT1 might affect p53 stability. To verify this, treatment with CHX, which inhibits protein synthesis, was carried out. The results showed that stability of p53 was increased by LUCAT1 knockdown ( Figure 7C ), suggesting that LUCAT1 influences p53 protein stability. MG132 treatment showed LUCAT1 affected p53 stability in proteasomedependent degradation ( Figure 7D ). Given that HCT116 and RKO cells possess the WT TP53 gene,
we used the SW480 cell line with mutant TP53 to test the effect of LUCAT1. As shown in Figure 7E ,F, LUCAT1 knockdown did not decrease SW480 cell viability, nor did it alter the expression levels of p21 or p53. These results indicated that the effect of LUCAT1 on cell proliferation and apoptosis might occur through the p53 pathway.
| LUCAT1 binds UBA52 to affect its stability
Recent studies have suggested that many lncRNAs directly bind proteins to participate in molecular regulation pathways. To investigate whether LUCAT1 functioned in a similar manner, we undertook chromatin isolation by RNA purification (ChiRP) assays using biotinlabeled probes specific for LUCAT1 and analyzed the precipitated proteins by mass spectrometry. Sixteen proteins that might potentially bind to LUCAT1 were identified by mass spectrometry ( Figure 8A ). Among these proteins, UBA52 was selected for further verification due to its better mass spectrometric data and its association with CRC. 12 We next undertook RNA immunoprecipitation (RIP) using anti-UBA52 in cell extracts from HCT116 cells. As shown in Figure 8B , LUCAT1 was enriched with anti-UBA52 Ab, but not with the IgG control. We also found that LUCAT1 knockdown upregulated F I G U R E 4 Lung cancer-associated transcript 1 (LUCAT1) promotes colorectal cancer cell invasion in vitro. Transwell assays were used to detect the migration (A) and invasion (B) of LUCAT1-knockdown and overexpressing cells after 36-48 h. Data represent mean ± SEM from 3 independent experiments. *P < .05, **P < .01 the expression of UBA52, whereas LUCAT1 overexpression downregulated UBA52 levels ( Figure 8C ). However, LUCAT1 knockdown or overexpression did not significantly affect the mRNA levels of UBA52 ( Figure 8C ) indicating that LUCAT1 might affect UBA52 protein stability. To verify this, CHX treatment was carried out, and the results showed that UBA52 stability was increased by LUCAT1 knockdown ( Figure 8D Figure 8E ). Together, these results suggested that LUCAT1 might physically bind with UBA52 and affect its stability in a proteasomedependent manner.
| Knockdown of LUCAT1 upregulates the RPL40-MDM2-p53 pathway
UBA52 is a hybrid gene encoding a fusion protein comprising ubiquitin at the N-terminus and 60S RPL40 at the C-terminus. Upon translation, ubiquitin and RPL40 are immediately cleaved from the translation product. 13 Previous studies have shown that RPs can regulate p53 stability through the RP-MDM2-p53 pathway responsible for ribosomal stress. 14 Our results showed that LUCAT1 knockdown significantly decreased the expression of rRNA, 18S RNA, and prerRNA ( Figure 9A ), which participate in ribosome biogenesis, indicating that LUCAT1 knockdown induced ribosomal stress. Previous studies showed that 5-FU treatment could trigger ribosomal stress and promote p53 accumulation by the RP-MDM2-p53 pathway. 15 As illustrated in Figure 9B , overexpression of LUCAT1 compromised p53 and MDM2 expression initially induced by 5-FU treatment. As UBA52 is cleaved into RPL40 and ubiquitin, we speculated that, in addition to the binding of RPL40 to MDM2, ubiquitin from UBA52 might participate in MDM2 ubiquitination, thus leading to its degradation by the proteasome system. To confirm this, we co-transfected MDM2 and UBA52 overexpression plasmids into HCT116 cells and undertook immunoprecipitation assays. The results showed ubiquitin from UBA52
bound to MDM2 ( Figure 9H ), suggesting that LUCAT1 knockdowninduced UBA52 might provide the ubiquitin pool to accelerate the degradation of MDM2. To examine whether overexpressed UBA52 reduced the expression of MDM2, we constructed a plasmid encoding WT UBA52 (UBA52-WT) and a cleavage-resistant UBA52 (UBA52-CR) and transfected them into HCT116 cells. Consistently, we found that UBA52-WT overexpression reduced the expression of MDM2 and increased p53 expression, whereas UBA52-CR had no effect on MDM2 and p53 expression ( Figure 9I ). This indicated that RPL40, cleaved from UBA52, functions to regulate the MDM2-p53 pathway, and ubiquitin from UBA52 regulates the stability of MDM2. We also found that UBA52-WT overexpression rescued the expression levels of p53 initially downregulated by LUCAT1 overexpression ( Figure 9J ). Together these data indicated that LUCAT1 downregulated p53 expression by binding to UBA52 to induce its degradation, which impairs the RPL40-MDM2-p53 pathway and releases more MDM2 for p53 degradation ( Figure 10 ).
| D ISCUSS I ON
In the present study, we revealed that the lncRNA LUCAT1 was highly expressed in CRC tissues through a transcriptome microarray undertaken in 6 pairs of CRC tissues and their corresponding lncRNA induces cell cycle arrest, apoptosis, and ferroptosis by binding with RAS GTPase-activating protein-binding protein 1, resulting in p53 retention in the nucleus. 27 In this regard, we undertook ChiRP and mass spectrometry followed by RIP and identified UBA52 as a binding protein to LUCAT1. UBA52, which is located on chromosome 19, is a hybrid gene encoding a fusion protein comprising ubiquitin at the N-terminus and RPL40 at the C-terminus. Upon translation, ubiquitin and RPL40 are immediately cleaved from the translated product. 13 Ubiquitin is the source of the ubiquitin pool and RPL40 participates in ribosomal biogenesis.
As a cellular "gatekeeper", p53 senses endo-and exogenous stressors and maintains cellular homeostasis by regulating cell proliferation, apoptosis, and senescence. 28 p53 is largely post-translationally regulated by MDM2, which is an E3 ubiquitin ligase that binds p53 to promote its degradation. 29 There are some regulatory factors that act on MDM2-p53. For example, p19 ARF inhibits MDM2-mediated p53 ubiquitination and degradation by binding with MDM2. 30 Recently, many studies have reported that a subset of ribosomal proteins including RPL5, RPL11, RPL26, RPS7, and RPS14 could bind to MDM2, inhibit its E3 ubiquitin ligase activity, and stabilize p53. 29, [31] [32] [33] [34] [35] This is the socalled RP-MDM2-p53 pathway, which responds to ribosomal stress or nucleolar stress. 29 Recent studies found that the RP-MDM2-p53 pathway could be regulated by several proteins such as SPIN1, which is highly expressed in ovarian cancer, showing oncogenic potential and preventing RPL5 from interacting with MDM2, thereby alleviating the RPL5-MDM2-p53 pathway.
36
In the present study, we found that RPL40, cleaved from UBA52 as a ribosomal protein, is involved in the RP-MDM2-p53 pathway by interacting with MDM2, and therefore causing the accumulation of p53. This RPL40-MDM2-p53 pathway accounts for LUCAT1 disruption-induced ribosomal stress characterized by the perturbation of ribosome biogenesis with decreased rRNA, 18S RNA, and pre-rRNA expression. In addition to the binding of RPL40 to MDM2, ubiquitin cleaved from UBA52 can also regulate MDM2 stability through ubiquitination. Our observation that overexpressed UBA52 abrogated LUCAT1-decreased p53 expression further supports this hypothesis.
In conclusion, this study found that LUCAT1 was significantly increased in CRC tissues and that suppression of LUCAT1 induced CRC cell cycle arrest and apoptosis, through binding UBA52 and activating the RPL40-MDM2-p53 pathway. Our data indicated that LUCAT1
is involved in CRC progression, and could serve as a potential prognostic biomarker and a therapeutic target for CRC.
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